Aptevo Therapeutics Inc. - FORM 10-K - EX-23.1 - March 31, 2017

Attached files

file filename
EX-31.1 - EX-31.1 - Aptevo Therapeutics Inc.apvo-ex311_441.htm
EX-32.1 - EX-32.1 - Aptevo Therapeutics Inc.apvo-ex321_439.htm
EX-32.2 - EX-32.2 - Aptevo Therapeutics Inc.apvo-ex322_438.htm
EX-31.2 - EX-31.2 - Aptevo Therapeutics Inc.apvo-ex312_440.htm
10-K - 10-K - Aptevo Therapeutics Inc.apvo-10k_20161231.htm

Exhibit 23.1

 

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-333-213108) pertaining to the 2016 Stock Incentive Plan and the Converted Equity Awards Incentive Plan of Aptevo Therapeutics Inc. of our report dated March 31, 2017, with respect to the consolidated financial statements of Aptevo Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2016.

 

 

/s/ Ernst & Young LLP

Seattle, Washington
March 31, 2017

 

 

 

Aptevo Therapeutics Inc. Reports